5099-39-8

Basic information

• Product Name: N⁽¹⁾-(2-(diethylamino)ethyl)-4-nitrobenzene-1,2-diamine
• Synonyms: N⁽¹⁾-(2-(diethylamino)ethyl)-4-nitrobenzene-1,2-diamine
• CAS NO: 5099-39-8
• Molecular Weight: 252.316
• Mol File: 5099-39-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N⁽¹⁾-(2-(diethylamino)ethyl)-4-nitrobenzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N⁽¹⁾-(2-(diethylamino)ethyl)-4-nitrobenzene-1,2-diamine(5099-39-8)
• EPA Substance Registry System: N⁽¹⁾-(2-(diethylamino)ethyl)-4-nitrobenzene-1,2-diamine(5099-39-8)

Safety Data

• Hazardous Substances Data: 5099-39-8(Hazardous Substances Data)

Upstream product

• 97-00-7 1-chloro-2,4-dinitro-benzene 
• 100-36-7 N,N-diethylethylenediamine 
• 16830-65-2 N-(2-chloroethyl)-2,4-dinitrobenzenamine 
• 1945-92-2 N-(2,4-dinitrophenyl)aminoethanol 
• 56223-91-7 N’-(2,4-dinitrophenyl)-N,N-diethylethane-1,2-diamine 

Downstream Products

• 14030-71-8 [2-(2-benzyl-5-nitro-benzoimidazol-1-yl)-ethyl]-diethyl-amine 
• 911-65-9 etonitazene 
• 3861-76-5 clonitazene 
• 95810-54-1 butonitazene 
• 14188-81-9 isotonitazene 
• 14680-51-4 metonitazene 
• 94758-81-3 4-((1-(2-(diethylamino)ethyl)-5-nitro-1H-benzo[d]imidazol-2-yl)-methyl)phenol 
• 110150-36-2 2-(4-chlorobenzyl)-1-[2-(diethylamino)ethyl]-1H-benzo[d]imidazol-5-amine 
• 75821-80-6 1-[2-(diethylamino)ethyl]-2-(4-ethoxybenzyl)-1H-benzo[d]imidazol-5-amine 

Relevant articles and documents

Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of "nitazene" 2-Benzylbenzimidazole Synthetic Opioids

Several 2-benzylbenzimidazole opioids (also referred to as "nitazenes") recently emerged on the illicit market. The most frequently encountered member, isotonitazene, has been identified in multiple fatalities since its appearance in 2019. Although recent

NOpiates: Novel dual action neuronal nitric oxide synthase inhibitors with μ-opioid agonist activity

A novel series of benzimidazole designed multiple ligands (DMLs) with activity at the neuronal nitric oxide synthase (nNOS) enzyme and the μ-opioid receptor was developed. Targeting of the structurally dissimilar heme-containing enzyme and the μ-opioid GPCR was predicated on the modulatory role of nitric oxide on μ-opioid receptor function. Structure-activity relationship studies yielded lead compound 24 with excellent nNOS inhibitory activity (IC50 = 0.44 μM), selectivity over both endothelial nitric oxide synthase (10-fold) and inducible nitric oxide synthase (125-fold), and potent μ-opioid binding affinity, Ki = 5.4 nM. The functional activity as measured in the cyclic adenosine monosphospate secondary messenger assay resulted in full agonist activity (EC50 = 0.34 μM). This work represents a novel approach in the development of new analgesics for the treatment of pain.